Prescription drug · BLA
Tecentriq (Atezolizumab) NDC 50242-917
Atezolizumab 1200 mg/20mL · Injection, Solution · Intravenous · Genentech, Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 50242-917-01 | 5024209170150242091701 | 1 VIAL, SINGLE-USE in 1 CARTON (50242-917-01) / 20 mL in 1 VIAL, SINGLE-USEMarketed from May 18, 2016 | |
| 50242-917-86 | 5024209178650242091786 | 1 VIAL, SINGLE-USE in 1 CARTON (50242-917-86) / 20 mL in 1 VIAL, SINGLE-USEMarketed from Aug 11, 2016 · Sample package |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Tecentriq
- Generic name (nonproprietary)
- atezolizumab
- Active ingredients
- Atezolizumab — 1200 mg/20mL
- Dosage form
- Injection, Solution
- Route
- Intravenous
- Labeler
- Genentech, Inc.NDC labeler code 50242
- Product type
- Prescription drug
- Marketing category
- BLA — Biologics License ApplicationApplication BLA 761034
- Marketing start
- Listing expires
- Other FDA classes
- Antibodies (Chemical structure)Monoclonal (Chemical structure)Humanized (Chemical structure)Programmed Death Receptor-1-directed Antibody Interactions (Mechanism)
- Identifiers
- Product ID 50242-917_4b922b35-c401-4189-a8b2-9f9a820878dbSPL ID 4b922b35-c401-4189-a8b2-9f9a820878dbSPL set ID 6fa682c9-a312-4932-9831-f286908660eeRxCUI 1792780, 1792785, 2119695, 2119696UNII 52CMI0WC3Y
- Pharmacologic class
- Programmed Death Receptor-1 Blocking Antibody
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeMed-Code curated
J9022 — Injection, atezolizumab, 10 mg
Billing unit: 10 mg. Units on the claim = dose given ÷ 10 mg.
- Administration
Drug administration (CPT 96360–96549)
When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.
- NDC on a medical claim
N450242091701followed by a unit qualifier and the quantityPackage 50242-0917-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
TECENTRIQ is a programmed death-ligand 1 (PD-L1) blocking antibody indicated: Non-Small Cell Lung Cancer (NSCLC) as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage II to IIIA NSCLC whose tumors have PD-L1 expression on ≥ 1% of tumor cells, as determined by an FDA-authorized test. ( 1.1 , 14.1 ) for the first-line treatment of adult patients with metastatic NSCLC whose tumors have high PD-L1 expression (PD-L1 stained ≥ 50% of tumor cells [TC ≥ 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥ 10% of the tumor area [IC ≥ 10%] ), as determined by an FDA-authorized test, with no EGFR or ALK genomic tumor aberrations. ( 1.1 …
Excerpt only. Read the full label for complete information.
About NDC 50242-917
- What is NDC 50242-917?
- 50242-917 is the product NDC for Tecentriq (atezolizumab), Atezolizumab 1200 mg/20mL injection, solution, listed with the FDA by Genentech, Inc.. It has 2 package NDCs, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Tecentriq (Atezolizumab).
- What is the active ingredient?
- Atezolizumab.
- Who is the labeler?
- Genentech, Inc., NDC labeler code 50242. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Tecentriq?
- 1 other product NDC are listed under this name. See all Tecentriq NDCs.
- Is there a related HCPCS / J-code?
- Yes: J9022, Injection, atezolizumab, 10 mg. See Billing references above.
Related NDCs: other Tecentriq products
Other finished products listed under the same name: strengths, forms and labelers.
| Product | Strength | Form · route | Labeler | Product NDC | Package NDCs (11-digit) |
|---|---|---|---|---|---|
| Tecentriqatezolizumab | Atezolizumab 840 mg/14mL | Injection, SolutionIntravenous | Genentech, Inc. | 50242-918 | 50242-0918-01 |
Other NDCs under BLA 761034
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Tecentriqatezolizumab | Atezolizumab 840 mg/14mL | Injection, SolutionIntravenous | Genentech, Inc. | 50242-918 |